Medical Device News Magazine

Lumenis Launches MOSES™ HoLEP University to Help Urologists Master the Gold-Standard Laser Treatment for Enlarged Prostate

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Lumenis, the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, today announced the launch of a comprehensive global educational platform called MOSES HoLEP University that will enable urologists to offer their patients holmium laser enucleation of the prostate (HoLEP) with MOSES, the gold-standard treatment for enlarged prostate (benign prostatic hyperplasia, or BPH).

By making HoLEP training available to any urologist at any time, the program will fill an educational gap. While interest in the procedure is expanding by 8% to 12% per year,1 opportunities for training remain limited due to restricted hospital foot traffic and travel during the COVID-19 pandemic.2

Lumenis responded to this demand for HoLEP education by joining forces with world-renowned physicians and BPH specialists Dr. Amy Krambeck of Northwestern Medicine and Dr. Tim Large of Indiana University Health. With help from Dr. Large, Dr. Krambeck will lead a one-of-a-kind opportunity for surgeons to master HoLEP through MOSES HoLEP University, an online, on-demand, module-based educational platform. Surgeons will observe a HoLEP procedure step by step, allowing them to achieve a full understanding of the technique. Training will be free to Lumenis customers using MOSES laser technology, winner of the prestigious Silver 2021 Medical Design Excellence Award in Gastrointestinal and Genitourinary Devices.

“MOSES HoLEP University was designed to facilitate more comprehensive learning with a faster learning curve,”3 said Dr. Krambeck. “Training will support urologists’ ability to effectively and efficiently perform HoLEP in men with BPH, regardless of their prostate size4 or history of taking blood thinners.”5

Accessed on demand, MOSES HoLEP University’s 14 modules explain how to perform different HoLEP techniques, including morcellation strategies, as well as how to set up a HoLEP practice, troubleshoot, and manage patient follow-up and concerns. In addition, trainees are invited to attend a MOSES Mastery course for hands-on lab and simulation experience. Following completion of MOSES HoLEP University, physicians can become adept at the HoLEP technique after 20 to 30 supervised procedures.6 In the future, each participant will be assigned a HoLEP mentor who can assist remotely with challenges.

HoLEP is a trusted procedure that has been improved by Lumenis MOSES technology. The Lumenis Pulse 120H laser with MOSES 2.0 technology shortens HoLEP procedure time by 20%, increases the rate of enucleation efficiency by 67%, and minimizes bleeding by 30%.7 As a result, more than 90% of patients can go home the same day, catheter-free,8 and only 0.7% of patients need retreatment in the next 10 years.9 MOSES has won multiple awards as a groundbreaking medical technology that is changing patient care.

“We are extremely proud to introduce this first-of-its-kind educational opportunity for surgeons who want to learn HoLEP with our breakthrough MOSES laser technology,” said Lumenis CEO Tzipi Ozer-Armon. “With unparalleled mentorship from recognized experts, MOSES HoLEP University will help surgeons satisfy patient demand for this important treatment, provide superior clinical outcomes, and elevate their practices.”


References:

1. IQVIA™ Hospital Procedures & Diagnosis US claims data coverage 2017-2019 (inpatient & outpatient).

2. Adopting Gold-Standard Procedures During COVID-19 – Patient Safety & Quality Healthcare (psqh.com).

3. Krambeck AE, Large T. Urology. 2020;136:196-201.

4. Elzayat EA, et al. Urology. 2005;66(5):108-113.

5. The HoLEP Procedure – Advanced Urology Institute – (auinstitute.com).

6. El-Hakim A., et al. BJU Int. 2002;90(9):863-9.

7. Kavoussi NL, et al. J Urol. 2021;206(1):104-108.8. Agarwal DK, et al. Eur Urol Focus. 2021 Jan 4.

8. Agarwal DK, et al. Eur Urol Focus. 2021 Jan 4.

9. Elmansy HM, et al. J Urol. 2011;186(5):1972-1976.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”